Dotti Patch, Extended Release
Product Images NDC 72162-2033

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Dotti (NDC 72162-2033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Dotti Estradiol Transdermal System 1)

Chemical structure of estradiol, the active ingredient in DOTTI transdermal patches, showing its molecular framework with hydroxyl groups and methyl substitution.*

FDA Label Image

4a (Dotti Estradiol Transdermal System 10)

An instructional illustration showing hands holding and peeling back a transdermal patch, demonstrating the application process for a patch dosage form.*

FDA Label Image

4b (Dotti Estradiol Transdermal System 11)

An instructional illustration showing two hands peeling apart a patch, demonstrating the correct way to remove the backing before application. The image is consistent with a transdermal patch product like DOTTI Estradiol extended-release patch.*

FDA Label Image

4c (Dotti Estradiol Transdermal System 12)

An instructional illustration showing a hand applying a small round transdermal patch to the lower abdominal area of the body. The image is likely related to the application of DOTTI (Estradiol) extended-release transdermal patches.*

FDA Label Image

4d (Dotti Estradiol Transdermal System 13)

Illustration showing hands applying a transdermal patch to the skin, demonstrating the proper method for placement of a DOTTI Estradiol extended-release patch.*

FDA Label Image

4e (Dotti Estradiol Transdermal System 14)

An instructional diagram showing hands applying a small rectangular transdermal patch to the skin, likely demonstrating use for a medication patch such as DOTTI estradiol extended-release patch.*

FDA Label Image

4f (Dotti Estradiol Transdermal System 15)

An instructional diagram showing a hand with a small rectangular patch applied to the upper side near the wrist, indicating transdermal application placement for a medication patch.*

FDA Label Image

4g (Dotti Estradiol Transdermal System 16)

An illustration showing the application of a DOTTI estradiol 0.0375 mg/d extended-release transdermal patch. The image depicts a hand placing the circular patch on the abdomen, indicating the typical site for patch application.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 2)

An illustration diagram showing a cross-sectional view of a transdermal patch labeled with three layers: (1) Backing, (2) Adhesive containing estradiol, and (3) Protective liner.*

FDA Label Image

Figure 1 (Dotti Estradiol Transdermal System 3)

A line graph depicting the concentration (pg/mL) of estradiol in the blood over time (days) for four different dosages: 0.1 mg/day, 0.075 mg/day, 0.05 mg/day, and 0.0375 mg/day. Concentration levels trend with varying fluctuations across the four dosage lines over a period of 4 days.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 4)

A bar graph comparing mean reduction from baseline over 12 weeks for Estradiol 0.0375 mg/day patch versus placebo. Bars represent values at Week 4, Week 8, and Week 12 showing greater reductions for Estradiol compared to placebo with statistical significance noted (p<0.05).*

FDA Label Image

2 (Dotti Estradiol Transdermal System 5)

A line graph depicting percentage change from baseline over treatment duration in weeks (26, 52, 78, 104) for different dosages of estradiol (0.1, 0.05, 0.0375, 0.025 mg/day) and placebo. Each dosage is represented by distinct lines, showing trends of change through the timeline.*

FDA Label Image

1 (Dotti Estradiol Transdermal System 6)

A line graph showing the percentage change from baseline over treatment duration up to week 104 for different dosages of estradiol (0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day) compared to placebo. The graph includes statistical significance markers indicating differences between groups at various time points.*

FDA Label Image

1 (Dotti Estradiol Transdermal System 7)

This image shows a usage guidance panel for DOTTI (estradiol transdermal system, USP). It instructs the user to change the patch only on specified two-day combinations, which are listed with checkboxes: Sun/Wed, Mon/Thu, Tue/Fri, Wed/Sat, Thu/Sun, Fri/Mon, and Sat/Tue.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 8)

Illustration showing a person applying a small, circular transdermal patch labeled DOTTI to the lower abdomen area. The diagram visually demonstrates the correct site for patch placement for the estradiol extended release formulation.*

FDA Label Image

3 (Dotti Estradiol Transdermal System 9)

An illustration showing a side profile of a person's upper torso, focusing on the placement area for a transdermal patch on the skin. The diagram is simple and outlines the body area where the DOTTI estradiol extended-release patch is to be applied.*

FDA Label Image

Label (Lbl721622033)

DOTTI estradiol transdermal system patch delivering 0.0375 mg/day, presented as an 8-system package. Label includes storage instructions, dosage strength, and manufacturer information showing Bryant Ranch Prepack as labeler and Amneal Pharmaceuticals as manufacturer. The label states the product is for transdermal use only and includes barcodes and lot/expiration details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.